Seminars in Cancer Biology

Article	Citations
Editorial Board	671
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	472
Small secretory proteins of immune cells can modulate gynecological cancers	426
Advances in biology and novel treatments of SCLC	390
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	386
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	332
Multifaceted role of chemokines in solid tumors: From biology to therapy	290
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects	260
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	255
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	246
Emerging applications of bacteria as antitumor agents	239
Critical DNA damaging pathways in tumorigenesis	238
Deregulated transcription factors in the emerging cancer hallmarks	236
Editorial Board	228
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	226
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	215
Gut microbes in gastrointestinal cancers	210
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	193
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	192
Immune cellular components and signaling pathways in the tumor microenvironment	191
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	187
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	183
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	170
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	166
Origins and molecular effects of hypoxia in cancer	164

Innovative trial design in precision oncology	163
The IL-1 family in tumorigenesis and antitumor immunity	162
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	162
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	161
Anticancer properties of chimeric HDAC and kinase inhibitors	159
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	159
The emerging role of metabolic interventions in uveal melanoma	158
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	155
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	152
Atrial fibrillation in cancer patients: Epidemiology, identification and management	145
The role of deiodinases on metabolic alteration in cancer	141
Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction	139
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	130
Editorial Board	130
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	129
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	129
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	129
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	127
Editorial Board	126
Reprogramming of glycolysis by chemical carcinogens during tumor development	126
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	122
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	120
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	118
Anticancer natural products targeting immune checkpoint protein network	117
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	112
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	108
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	106
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	105
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	103
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	102
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	101
Editorial Board	98
How far have we explored fungi to fight cancer?	98
Editorial Board	98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	98
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	92
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	92
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	92
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?	92
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	92
Editorial Board	92
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	91
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	91
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	91
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	89
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	88
Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives	88
Microbiota and lung cancer	87
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	83
Clinical utility of whole-genome sequencing in precision oncology	83

Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	83
Microorganisms in cancer tertiary lymphoid structure formation	82
Analytical demands to use whole-genome sequencing in precision oncology	81
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	81
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	81
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	80
Advancements in small cell lung cancer	80
Metabolic reprogramming of tumor microenviroment by engineered bacteria	80
Editorial Board	79
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	78
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	77
Holistic immunomodulation for small cell lung cancer	77
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	77
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	76
Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease	76
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	76
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	75
CRISPR/Cas mediated epigenome editing for cancer therapy	74
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	74
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	74
Anticancer activity of lactic acid bacteria	73
Editorial Board	73
Excess body weight: Novel insights into its roles in obesity comorbidities	73
Editorial Board	72
Thematic issue ‘tumor glycolysis’	71
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	71
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	71
Editorial Board	71
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	70
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	70
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	70
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	69
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	69
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	69
The impact of VEGF on cancer metastasis and systemic disease	68
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	67
Deregulated transcription factors and poor clinical outcomes in cancer patients	67
TGF-β, EMT, and resistance to anti-cancer treatment	66
Transcriptional factors targeting in cancer stem cells for tumor modulation	65
Editorial Board	65
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	65
Gut microbiota and immunosenescence in cancer	64
The intricate nature of senescence in development and cell plasticity	64
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	64
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	63
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	63
Precision diagnostics in lymphomas – Recent developments and future directions	62
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	62
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	61
Obesity, type 2 diabetes and cancers of the digestive system	61
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	61
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	60
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	60
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	60
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	60
Alternative splicing in EMT and TGF-β signaling during cancer progression	59
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	59
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	58
cGAS/STING signalling pathway in senescence and oncogenesis	58
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	57
Artificial intelligence aids in development of nanomedicines for cancer management	57
Editorial Board	57
Nanoparticles: Attractive tools to treat colorectal cancer	55
Editorial Board	55
Vitamin D: What role in obesity-related cancer?	55
Editorial Board	55
Precision medicine in pediatric solid cancers	54
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	54
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	54
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	54
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	53
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	53
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	53
The altered lipidome of hepatocellular carcinoma	52
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	52
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	52
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	51
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	51
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	51
Small cell lung cancer: Novel treatments beyond immunotherapy	50

Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	50
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	50
Hedgehog signaling mechanism and role in cancer	50
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	49
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	49
The role of gut microbiota in obesity-related cancers	49
Nutrient sensing of mTORC1 signaling in cancer and aging	49
Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics	48
Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity	48
Ethical challenges of precision cancer medicine	48
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells	48
The two sides of Hippo pathway in cancer	48
Understanding RNA-binding proteins	48
Obesity and GEP-NEN: what’s new?	47
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	47
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	47
Editorial Board	47
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	47
Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes	47
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	47
Epigenetic Regulation of Cancer Immune Cells	46
RB functions as a key regulator of senescence and tumor suppression	46
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy	46
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence	46
Therapy-driven clonal dynamics in chronic lymphocytic leukemia	46
Harnessing computational spatial omics to explore the spatial biology intricacies	45
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	45
A systems and computational biology perspective on advancing CAR therapy	45
Obesity and renal cell carcinoma: Biological mechanisms and perspectives	45
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer	45
Targeting cancer stem cells by nutraceuticals for cancer therapy	45
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations	45
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells	44
Expression of concern “Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies” [Semin. Cancer Biol. 111 (2025) 16–35]	44
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs	44
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis	44
Expression of concern “Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions” [Semin. Cancer Biol. 109 (	44
Vaginal microbiome and cervical cancer	44
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard	43
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	43
Special issue on “Excess body weight and cancer: Novel biologic insights and challenges”	43
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	42
Status quo of Extracellular Vesicle isolation and detection methods for clinical utility	42
The cell cycle revisited: DNA replication past S phase preserves genome integrity	42
Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors	42
Cancer cell populations	41
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	41
Editorial: Regulating cell cycle-related activities: The right target for cancer therapy	41
Insulin resistance in cancer risk and prognosis	41
Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?	41
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression	41
Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy	41
High-Throughput immunogenetics for precision medicine in cancer	40
Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity	40
Extracellular vesicles for precision medicine in prostate cancer – Is it ready for clinical translation?	40
Expression of concern “T-cell senescence: Unlocking the tumor immune “Dark Box” – A multidimensional analysis from mechanism to tumor immunotherapeutic intervention” [Semin. Cancer Biol. 113 (2025) 19	40
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1	40
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]	40
Expression of concern “DAMPs in immunosenescence and cancer” [Semin. Cancer Biol. 106–107 (2024) 123–142]	40
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany	39
The potential of liquid biopsy in the management of cancer patients	39
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression	39
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review	38
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma	38
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer	38
Editorial Board	38
Chemokines network in bone metastasis: Vital regulators of seeding and soiling	38
Dietary molecules and experimental evidence of epigenetic influence in cancer chemoprevention: An insight	37
What we know on the potential use of exosomes for nanodelivery	36
Aberrant transcription factors in the cancers of the pancreas	36
Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis	36
99mTC-sestamibi breast imaging: Current status, new ideas and future perspectives	36
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies	35
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges	35
Editorial Board	35
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update	34
Targeting intratumoral hypoxia to enhance anti-tumor immunity	34
Comparative analysis of the minimal information for studies of extracellular vesicles guidelines: Advancements and implications for extracellular vesicle research	34
Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity	34
Microbial modulation as a game changer: Boosting immunotherapy efficacy in breast cancer	34
RNA-binding proteins: Underestimated contributors in tumorigenesis	34
Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy	34
Nutrition and upper gastrointestinal cancers: An overview of current understandings	33
The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer	33
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy	33
Editorial: Role of chemokines in tumor heterogeneity	33
Nanomedicines: Targeting inflammatory pathway in cancer and aging	32
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	32
Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis	32
The second half of mitosis and its implications in cancer biology	32
Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview	32
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	32
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies	32
Reshaping the immune microenvironment and reversing immunosenescence by natural products: Prospects for immunotherapy in gastric cancer	32
CDK inhibitors from past to present: A new wave of cancer therapy	32